Meet the inaugural class of InSIGHTful Academy!

June 16, 2025

Download PDF Version

By Rigo Magana

Events

On May 17th, 2025, Sight Sciences proudly launched its first-ever InSIGHTful Academy Live in the vibrant city of Nashville. This inaugural event welcomed an outstanding group of residents, fellows, and recent graduates from 16 academic institutions for a day designed to educate, connect, and inspire.

A Vision for the Future of Eyecare

The InSIGHTful Academy program is built to support the next generation of eyecare professionals by offering a collaborative, hands-on learning experience that goes beyond traditional education. Through real-world insights, expert mentorship, and practical labs, participants gained a deeper understanding of interventional glaucoma and its growing role in modern clinical practice.

An Action-Packed Agenda

The day began with breakfast and a welcome session followed by a deep dive into the evolving landscape of interventional glaucoma care:

Setting the Stage – Modern Glaucoma Care
Interventional Glaucoma in Practice
Surgical Case Reviews – Roundtable Discussion
The Pseudophakic Patient: Harnessing the Interventional Mindset
Didactic Review of the OMNI® Surgical System
Hands-On Skills Lab

The day concluded with closing remarks, followed by a lively evening dinner at The Diner Nashville—offering a chance for attendees to relax, reflect, and forge new connections.

Thanks to an Incredible Community

We are deeply grateful to the 2025 InSIGHTful Academy class for their energy, engagement, and passion for advancing eyecare. A special thank you to our distinguished faculty—Drs. Jella An, Matt Brink, Reena Garg, and Nina Goyal—and our program chair, Dr. Nathan Radcliffe, for shaping this impactful experience. We’re also grateful to Bryn Mawr Communications for their invaluable partnership and contributions.

Looking Ahead

InSIGHTful Academy is more than a single event—it’s a long-term investment in the clinical and professional development of eyecare professionals. We are excited to continue building on this momentum and to keep offering unique, valuable experiences that empower the next generation of glaucoma specialists. Stay tuned for more highlights and upcoming events. For more information, contact us at glaucoma@sightsciences.com.

InSIGHTful Academy Picture 1

InSIGHTful Academy Picture 2

InSIGHTful Academy Picture 3

InSIGHTful Academy Picture 4

InSIGHTful Academy Picture 5

InSIGHTful Academy Picture 6

InSIGHTful Academy Picture 7

InSIGHTful Academy Picture 8

InSIGHTful Academy Picture 9

InSIGHTful Academy Picture 10

InSIGHTful Academy Picture 11

InSIGHTful Academy Picture 12

InSIGHTful Academy Picture 13

InSIGHTful Academy Picture 14

InSIGHTful Academy Picture 15

InSIGHTful Academy Picture 16

InSIGHTful Academy Picture 17

InSIGHTful Academy Picture 18

InSIGHTful Academy Picture 19

InSIGHTful Academy Picture 20

InSIGHTful Academy Picture 21

© 2025 Sight Sciences. All rights reserved. Physicians are paid consultants of Sight Sciences. 06/2025 SS-3545-US.v1

Latest Posts

July 12, 2025

Sightfluencers: Monisha Vora, MD Read More

July 7, 2025

Case of the Month: By Arkadiy Yadgarov, MD Read More

June 3, 2025

How to Successfully Implement Standalone MIGS in Your Practice Read More

Additional Blog Posts

May 2, 2025

Join us at ASCRS 2025 in Los Angeles Read More

February 14, 2025

Five Reasons to Join Sight Sciences at AGS 2025 in Washington DC Read More

Want to speak to one of our representatives?

Contact Us

Important Product Information

INDICATIONS FOR USE

The TearCare^® System is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands.

CONTRAINDICATIONS

^®

Recent (i.e. within the last 90 days) surgical procedure to the eye or eyelid.
Recent ocular injury.
History of Herpes Simplex or Herpes Zoster of the eye or eyelid.
Active ocular or periocular infection, inflammation or irritation.
Diminished or abnormal facial, periocular, ocular, or corneal sensation.
Ocular surface ulcers.
Hordeolum, stye, or chalazion.
Do not use the TearCare® System in patients under the age of 22 years.
Pacemakers or implantable cardiac defibrillators (ICD). Use of the TearCare® System may affect the performance of pacemakers or ICD’s due to electromagnetic interference (EMI). To avoid any potentially serious safety effects, patients with these implants should not be treated with the TearCare^® System.
Known allergy to acrylate.
Known allergy to silicone tissue adhesives.
Known allergy to copper.

WARNINGS

Do not use the TearCare^® System outside the instructions for use. Doing so can result in unanticipated patient harm.
Do not attempt to connect the SmartHub^™ or SmartLid^™ directly to an electrical outlet of any kind.
Do not use the TearCare^® System in or near an MRI suite or near a magnetic field. Serious injury can occur to a patient or technician if a TearCare^® System is brought into an MRI suite.
The TearCare^® System has not been tested in the presence of flammable anesthetics or other flammable agents in combination with air, nitrous oxide, or oxygen enriched environments.
Do not apply SmartLids to non-intact skin (i.e., skin with active abrasion, cut, burn, rash, inflammation, redness, etc.)

PRECAUTIONS

Use of the TearCare^® System in patients with eyelid abnormalities (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis, etc.) may result in poor adhesion of the SmartLid^™ to the eyelid and/or reduced benefit.
Use caution when using the TearCare^® System in patients with ocular surface abnormalities (e.g. pterygium, pingueculum, corneal dystrophies, etc.) as the heat delivered by the System may aggravate these conditions.
Remove contact lenses from the patient’s eyes prior to use of the TearCare^® System. Patients should wait 60 minutes after the completion of the TearCare^® procedure before re-inserting contact lenses.
Do not apply the SmartLids^™ to any other part of the patient’s body including the cornea. The SmartLids^™ are only intended for application on the external surface of the patient’s eyelids.
It is important for patient to keep their eyes open (blinking is permitted) during treatment, to allow heat to dissipate off of the ocular surface.
Effectiveness of the TearCare^®System has not been established in subjects for whom the treatment temperature is lowered from Warmth Level Setting #5 due to patient pain or discomfort.
Do not reuse the SmartLids^™. Cross-contamination can occur if re-use is attempted.
Do not use a TearCare^® System, its components, or accessories that appear damaged. Inspect all components for damage before each use.
The safety and effectiveness of the TearCare^®System is not known in the following patient populations that were excluded in the OLYMPIA pivotal study: patients under 22 years of age, dry eye signs and symptoms other than meibomian gland dysfunction, severe signs and symptoms of dry eye due to meibomian gland dysfunction (OSDI > 79), mild signs and symptoms of dry eye due to meibomian gland dysfunction, and other study exclusions described in the TearCare^®Instructions for Use.

POTENTIAL ADVERSE EVENTS

Potential adverse events may include but are not limited to:

Eyelid or eye pain requiring discontinuation of the treatment procedure
Eyelid irritation or inflammation*
Ocular surface irritation or inflammation*
Ocular symptoms (such as burning, redness, tearing, visual disturbance, redness)
Burn, erythema, or swelling of the eyelids
Conjunctival infection (moderate or severe)
Conjunctival abrasion
Corneal abrasion
Corneal deformation
Allergic or inflammatory reaction to medical adhesive on the SmartLid device
Formation of a chalazion or stye*
Decline in visual acuity*
Worsening of dry eye symptoms*
Increased discomfort or pain of ocular surface (grittiness, foreign body sensation, etc.)
Discomfort or pain of eyelids or orbit*
There is a potential risk of thermal injury to eye or eyelid based on the device design.

Access the Full TearCare Instructions for Use